Navigation Links
Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
Date:12/8/2008

Lead Oral Candidate Demonstrates Proteasome Inhibition and Anti-Tumor Activity

SOUTH SAN FRANCISCO, Calif., Dec. 8 /PRNewswire/ -- Proteolix, Inc., today announced results from a series of in vitro and in vivo studies designed to characterize PR-047, the company's oral proteasome inhibitor. These data were presented today in a poster titled "Preclinical Pharmacology and In Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome" (Abstract # 3671) at the 50th Annual Meeting of the American Society of Hematology (ASH). PR-047 is the first oral compound in a new class of highly specific proteasome inhibitors. Carfilzomib, the lead compound in this class, will be the subject of two oral presentations of Phase 2 data on Tuesday, December 9th. PR-047 was designed by Proteolix scientists to combine the pharmacological properties of carfilzomib with the convenience of oral dosing.

Researchers evaluated PR-047's mechanism, bioavailability and activity in a series of preclinicalstudies. Like carfilzomib, PR-047 was shown to target the chymotrypsin-like activity of the proteasome and induce tumor cell death across multiple human cell lines. Oral administration of PR-047 in rodents and monkeys resulted in rapid and prolonged dose-dependent inhibition of the proteasome. Furthermore, significant proteasome inhibition was achieved at doses well below the maximum-tolerated dose even when administered over five consecutive days, suggesting that repeated daily dosing may be feasible with this molecule. Administration of PR-047 resulted in consistent anti-tumor responses in hematological and solid tumor xenograft models at doses below the maximum-tolerated dose.

"We are pleased by the preclinical data achieved to date with PR-047, which demonstrates a promising combination of proteasome inhibition, anti-tumor activity, bioavailability and tolerability," said Mark
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Proteolix Raises $79 Million in Series C Financing
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
5. AmeriCares Presents Power of Partnership Award to Baxter
6. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
7. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
9. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
10. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Dec. 2 Peregrine Pharma...mpletion of patient enrollment in a dose confirmat...s with relapsed glioblastoma multiforme (GBM), the...eted monoclonal antibody linked to a radioisotope ...BM. Cotara specifically targets cells at the cent...
(Date:12/2/2009)...EM, Israel, December 2 Gamida Cell...e preclinical (animal study) safety and,efficacy o... from Weill,Cornell Medical College and Gamida Cel...ed anemias such as Cooley,s Anemia. , Gam... expand, ex vivo,populations of stem/progenitor c...
(Date:12/2/2009)...ec. 2 /PRNewswire-Asia/ -- The world is going thro...d uncertainty is part of many,businesses and indus...een,relatively immune to the economic downturn, be...During the midst of the difficult times this year,...augurated an R&D center in Shanghai, the large...
(Date:12/1/2009)...c. 1 Reportlinker.com announces th...s catalogue: ,, Chromium - Global Market Tren...hromium---Global-Market-Trends.html ,, Worldwi...stainless steel, while growth in aerospace and ind...growth of chromium metal. Environmental constraint...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9
...., Oct. 5 Bionovo, Inc.,(Nasdaq: BNVI ), a leade...ective drugs in the areas of women,s health and ca... CFO of Bionovo, Inc., will present at the 4th,Ann...e place on October 11, 2007 at 12:30 p.m. PDT,at t...o web cast and slide presentation of the event wil...
...CO, Calif., Oct. 5 Cerimon,Pharmaceuticals, Inc.,...and,Chief Executive Officer, will present at the 2...07, at 9:30 a.m. PDT at the Palace Hotel in San,Fr...acific Heights room. About Cerimon Pharmaceutical...tical company dedicated,to developing and commerci...
...5 The Coalition for a,Competitive Pharmaceutical ... on the Food and Drug Administration,s announcemen...Efficiency" (GIVE): "With consumers, employers, i...nage escalating prescription drug costs, it is cri...ays to enhance timely generic access.,Today,s anno...
Other Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2
(Date:12/3/2009)...ds the world when it comes to investment in energy...and Physical Sciences Research Council (EPSRC) Chi...ed: "Scientific and engineering research has alrea...ower solutions, but more investment is needed to d...we are to meet our carbon emission targets by 2020...
(Date:12/2/2009)...PHIA Children exposed to secondhand cigarette smo...r in adulthood, even if they never smoked. , Re...miology, Biomarkers & Prevention , a journal of th...t of a special tobacco focus in the December issue...s will be diagnosed with lung cancer; more than 15...
(Date:12/2/2009)...PHIA Cigarette smoking and alcohol consumption be...cts the patient,s future risk of death, according ...show a similar effect among those who continued th...r survivors are counseled to quit smoking; despite...continued to smoke even after their cancer diagnos...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Syngenta Issues EUR 500 Million Eurobond 12745 1Syngenta Issues EUR 500 Million Eurobond 12745 2Physician Receives Bachelors Degree After 50 Years 49750 1Physician Receives Bachelors Degree After 50 Years 49750 2Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 1Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 2Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 3Helix Biopharma Corp Begins Trading on the OTCQX International Market Listing as HXBPF 49749 4
...ls Network, an initiative designed to address the ...tegration of imaging biomarkers into multi-center ... a supporter. , SNM, the world,s largest medical ...ssionals, inaugurated the Clinical Trials Network ...g development through the integration and standard...
...al of a tissue sample is now the standard for diag... are accurate but only offer a snapshot of the tum...or for weeks or months after the biopsy, tracking ... be much more valuable, says Michael Cima, MIT pro...as developed the first implantable device that can...
...erican Society of Civil Engineers (ASCE) has prese...ng, Stabile Professor for Innovation and Technolog... as an expert, contact Sheryl Weinstein at 973-596...f civil and environmental engineering, has 35 year...ivil engineering in both the academic field and pr...
Other Biology News:SNM's clinical trials network gains added support from industry leader 2MIT’s implantable device offers continuous cancer monitoring 2Civil engineers name NJIT's John Schuring Educator of Year Award 2
...ified Formulation: 50mM Tris-HCl, pH 7.5, 0.1mM EG...1% 2-mercaptoethanol and 50% glycerol. Properites:...d enzyme Purification: DEAE-Sephadex, ammonium sul..., Superdex 200, and Mono Q chromatography to >95%....
Beacon 2000 One-Step FP Std from Invitrogen
Beacon 2000 Chamber (6mm, Minimum Vol - 100 uL) from Invitrogen
EvoQuest Custom Peptide Services from Invitrogen
Biology Products: